Melbourne researchers have shown they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth.
The researchers discovered that targeting a protein called Hhex could cure acute myeloid leukaemia (AML) in preclinical disease models, and could be a key target for new therapies for human leukaemia.
Dr Ben Shields and Dr Matt McCormack from the Walter and Eliza Hall Institute’s Cancer and Haematology division discovered that loss of the Hhex protein put the handbrake on leukaemia cell growth and division. The protein is a critical factor enabling AML cells to grow uncontrollably, a hallmark of cancer.
AML is an aggressive blood cancer that appears suddenly, grows quickly and has a poor prognosis. Existing treatments for AML are associated with serious side-effects. About three quarters of patients relapse after only a short period of treatment, with a five-year survival rate of just 24 per cent.
Dr McCormack said discovering how AML overcame normal cellular controls on growth and division was a breakthrough in the search for new therapies.
“There is an urgent need for new therapies to treat AML,” said Dr McCormack. “We showed blocking the Hhex protein could put the brakes on leukaemia growth and completely eliminate AML in preclinical models. This could be targeted by new drugs to treat AML in humans.”
He said Hhex was a particularly attractive therapeutic target because it was overproduced in leukaemia and, while essential for leukaemia cell growth, was not needed by healthy blood cells.
“Most existing treatments for AML are not cancer cell-specific, and unfortunately kill off healthy cells in the process,” Dr McCormack said.
“Hhex is only essential for the leukaemic cells, meaning we could target and treat leukaemia without toxic effects on normal cells, avoiding many of the serious side-effects that come with standard cancer treatments. We also know that most people with AML have increased levels of Hhex, often associated with adverse outcomes, further indicating it is an important target for new AML drugs.”
Dr Shields said AML cells switched off the controls that strictly manage cell growth and division. “Every cell has control genes that are activated when a cell is stressed, such as in the early stages of cancer, and stop the damaged cell from reproducing.” Dr Shields said.
While these control genes are still present in AML cells, they are switched off through a process called epigenetic modification. “Hhex works by recruiting epigenetic factors to growth control genes, effectively silencing them. This allows the leukaemia cells to reproduce and accumulate more damage, contributing to the speed of AML progression,” Dr Shields said.
Dr McCormack said drugs that inhibit epigenetic modification had been previously used to treat AML, but caused significant toxicity because their targets were also required for normal blood cell function.
“Unlike the epigenetic factors targeted previously, Hhex only regulates a small number of genes and is dispensable for normal blood cells. This gives us a rare opportunity to kill AML cells without causing many side effects,” said Dr McCormack. “We now hope to identify the critical regions of the Hhex protein that enable it to function, which will allow us to design much-needed new drugs to treat AML.”
The Latest on: Leukaemia
via Google News
The Latest on: Leukaemia
- No country and no work: refugees despair at slow pace of Malaysia's reformson August 15, 2019 at 6:33 am
His two-year-old daughter Mahdya is battling leukaemia and needs a stem cell transplant, but with no work there is little chance he can pay the 250,000 Malaysian ringgit ($60,000) cost.
- Three-year-old Annas Mikhail succumbs to leukaemiaon August 14, 2019 at 7:21 pm
PARIT BUNTAR, Aug 15 (Bernama) -- Toddler Annas Mikhail Abdullah, three, a chronic leukaemia patient died early this morning at Hospital Pulau Pinang. His grandmother, Faridah Wan Chik, 48, said the ...
- New treatment option for certain leukaemia patients in Scotlandon August 14, 2019 at 9:54 am
A targeted combination treatment for patients with a specific type of blood cancer will soon be available on the NHS in Scotland. Following the recommendation by the Scottish Medicines Consortium (SMC ...
- TOP NEWS: AstraZeneca Leukaemia Drug Gets US Regulatory Designationon August 14, 2019 at 1:17 am
(Alliance News) - AstraZeneca PLC on Wednesday said its Calquence remedy received breakthrough therapy designation, while trials showed the drug maker's Lynparza medication allowed ovarian cancer ...
- Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemiaon August 13, 2019 at 11:27 pm
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for adult ...
- Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemiaon August 13, 2019 at 2:20 am
Genomic alterations in cancer are heterogeneous and complex but mainly thought to disturb protein function or gene expression 1. The extent to which such mutations are transcribed into RNA is largely ...
- Mother who dismissed her headaches and fatigue as pregnancy symptoms is diagnosed with LEUKAEMIA and has to delay treatment to have her babyon August 11, 2019 at 10:08 pm
A mother who dismissed her headaches and fatigue as symptoms of pregnancy was diagnosed with leukaemia and delayed her treatment to have her baby. Kerri Hannay, 33, credits her doctor for spotting a ...
- Mum went to doctors feeling a 'bit rundown' and was told she had leukaemiaon August 10, 2019 at 9:30 pm
Like many mums, Julie McNeill was busy and felt a 'bit rundown.' She'd just moved house and was looking after her poorly mum whilst working and running around after her three kids. A couple of colds ...
- Brave Telford youngster Zac Oliver, 5, who battled with leukaemia given the all-clearon August 7, 2019 at 6:12 am
Brave Telford youngster Zac Oliver who battled with a rare type of childhood leukaemia has been given the all-clear in his latest tests. Five-year-old Zac and his family, who live in Broseley, flew ...
- Tributes as Norfolk mum-of-four loses four-year battle with leukaemiaon August 6, 2019 at 7:55 am
Heather Bellamy, from Downham Market, who had been fighting acute myeloid leukaemia for four years, died on Saturday, August 3. Friends and family had been desperately trying to raise £250,000 to send ...
via Bing News